by NanoLogix | May 3, 2020 | updates
Last week NanoLogix completed development testing of a unique Coronavirus (COVID-19) detection technology with sub 1-hour results and exceptional sensitivity and accuracy. The technology has the potential to be configured as a Point of Care (POC) and also for...
by NanoLogix | Apr 28, 2017 | updates
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, recently configured for detection and identification of a rare Deinococcus bacteria species, will be presented in poster format at the American Association for Clinical Chemistry (AACC) 69th Annual...
by NanoLogix | Aug 14, 2014 | updates
HUBBARD, Ohio–(BUSINESS WIRE)–NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that it is configuring its N-Assay Rapid diagnostic kits for both Ebola Virus and Enterovirus detection and identification. NanoLogix...
by NanoLogix | Aug 1, 2011 | updates
NanoLogix Group B Streptococcus Quick Test technology is currently undergoing a 300-patient clinical study at the University of Texas Health Science Center (UTHSC). Preliminary results published in the American Journal of Perinatology (August 2011) “Rapid...
